Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multi-center, Randomized, Partially Double Blinded, Placebo Controlled Study, to Evaluate the Safety of Daily Inhaled Zanamivir 10 mg Versus Placebo and Daily Oral Oseltamivir 75 mg Versus Placebo for Influenza Prophylaxis in Healthy Volunteers for 16 Weeks

NCT00980109 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT00980109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00980109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multi-center, Randomized, Partially Double Blinded, Placebo Controlled Study, to Evaluate the Safety of Daily Inhaled Zanamivir 10 mg Versus Placebo and Daily Oral Oseltamivir 75 mg Versus Placebo for Influenza Prophylaxis in Healthy Volunteers for 16 Weeks
Lead sponsor
University of Oxford
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2009
Completion date
September 30, 2010
Enrollment
390 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza